Sacubitril/Valsartan in the Treatment of Resistant Hypertension: Raising Star or Illusion?

Published in: Journal of clinical medicine (2022)

Sacubitril/valsartan represents the combination that became " sine qua non " in the treatment of heart failure with reduced ejection fraction (HFrEF) with significant positive effect on major cardiovascular events [...].

Keyphrases

cardiovascular events
heart failure
coronary artery disease
cardiovascular disease
blood pressure
type diabetes
ejection fraction
atrial fibrillation
smoking cessation